GlycoMimetics Inc(GKO)

Description: GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

---

Keywords: Biotechnology Cancer Chemotherapy Acute Myeloid Leukemia Inflammatory Diseases Glycoproteins Clusters Of Differentiation National Cancer Institute Lectins Osteosarcoma Galectin 3 Therapies For Cancers E Selectin

---

Home Page: www.glycomimetics.com

9708 Medical Center Drive
Rockville, MD 20850
United States
Phone: 240 243 1201

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)